Stifel Maintains Buy on Conmed, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise has maintained a 'Buy' rating on Conmed (NYSE:CNMD) but lowered the price target from $136 to $120.
October 26, 2023 | 7:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel analyst has maintained a 'Buy' rating on Conmed but lowered the price target from $136 to $120.
The news is directly related to Conmed (CNMD). While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100